Prospective, monocentric, observational study of the long-term effectiveness of omalizumab in chronic urticaria [0.03%]
在慢性荨麻疹中长期观察奥马利珠单抗疗效的单中心前瞻性观察研究
Stephan Traidl,Bettina Wedi
Stephan Traidl
Omalizumab, a monoclonal antibody targeting IgE, has been approved in 2014 for the treatment of H1 antihistamine-refractory chronic urticaria. Data on long-term effectiveness and predictive factors for treatment response are currently limit...
Case report: Severe chronic spontaneous urticaria successfully treated with omalizumab and dupilumab [0.03%]
病例报告：用奥马利珠单抗和杜普利鲁玛成功治疗严重慢性自发性荨麻疹
Viktoria Puxkandl,Wolfram Hoetzenecker,Sabine Altrichter
Viktoria Puxkandl
Urticaria is a disease triggered by mast cells and characterized by recurrent symptoms such as wheals and/or angioedema. Most patients benefit from treatment with antihistamines (AH) or, if not effective enough, from additional therapy with...
Case Reports
Allergologie select. 2023 Jan 3:7:17-19. DOI:10.5414/ALX02382E 2023
Chronic recurrent wheals - If not chronic spontaneous urticaria, what else? [0.03%]
慢性反复发疹 - 如果不是慢性自发性荨麻疹，还会是什么呢？
Hanna Bonnekoh,Karoline Krause,Pavel Kolkhir
Hanna Bonnekoh
Chronic urticarial rash, mostly due to chronic spontaneous urticaria (CSU), is seen in up to 1 - 4% of the general population. Urticarial vasculitis (UV) and autoinflammatory syndromes, i.e., cryopyrin-associated periodic syndromes (CAPS) a...
Alpha-gal syndrome and delayed anaphylaxis after ingestion of red meat: A case report [0.03%]
红肉摄入后迟发型过敏性休克伴阿尔法半乳糖综合征：一例报道
Lea Caron,Valeria G R Ortolani,Eleonora Bono et al.
Lea Caron et al.
α-gal syndrome (AGS) is caused by the intake of products containing α-gal (galactose-α-1,3-galactose) like mammalian meat. Over the last decade, scientific literature about AGS has been increasing, but the true burden of cases is still u...
Case Reports
Allergologie select. 2022 Dec 15:6:299-303. DOI:10.5414/ALX02394E 2022
Stephanie Dramburg,Paolo Maria Matricardi,Oliver Pfaar et al.
Stephanie Dramburg et al.
In the recent past, digital healthcare technologies are experiencing a significant leap in development, with an additional unforeseen acceleration in implementation due to the SARS-CoV-2 pandemic. The increased use of mobile applications as...
Adherence in allergen immunotherapy: Current situation and future implications [0.03%]
过敏原免疫治疗中的依从性：现状与未来意义
Francesca Gehrt,Qingqing Xu,Ilaria Baiardini et al.
Francesca Gehrt et al.
Allergen immunotherapy (AIT) is the only disease-modifying treatment in allergy. However clinical trials as well as real-life studies revealed poor treatment adherence. This article is intended to provide an overview of the current literatu...
Antonella Muraro,Angelo Tropeano,Mattia Giovannini
Antonella Muraro
Food allergy represents a significant health issue characterized by a sizeable epidemiological burden, involving up to 5% of adults and up to 8% of children in the Western world. The elimination diet of the trigger food is the cornerstone o...
Tiak Ju Tan,María I Delgado-Dolset,María M Escribese et al.
Tiak Ju Tan et al.
Allergic rhinitis is an IgE-mediated inflammation that remains a clinical challenge, affecting 40% of the UK population with a wide range of severity from nasal discomfort to life-threatening anaphylaxis. It can be managed by pharmacotherap...
Pattraporn Satitsuksanoa,Alba Angelina,Oscar Palomares et al.
Pattraporn Satitsuksanoa et al.
Background: Allergen-specific immunotherapy (AIT) is currently the only treatment with potential long-term disease-modifying effects for patients suffering from allergic diseases such as allergic rhinitis, allergic asthma...
111 years of allergen-immunotherapy: A long and successful history of the only available disease-modifier in allergic diseases [0.03%]
过敏性疾病变应免疫治疗的长期成功历史及其作为唯一疾病修饰疗法的作用：111年历程
Jan Gutermuth,Martine Grosber,Oliver Pfaar et al.
Jan Gutermuth et al.
The great milestones in medicine almost always have their precursors, which help the great event to break through. So it was with allergen-specific immunotherapy (AIT) and the great work of Noon and Freeman and their world-renowned publicat...